FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to laboratory diagnostics, and can be used for prediction of severe preeclampsia (PE) in pregnancy in females, carriers of mutation of prothrombin gene (factor 2), genotype G20210A, by prothrombin activity detection in gestation period of 7–8 weeks. A method for predicting preeclampsia involves determining prothrombin activity by using substrate-deficient plasma, and if observing prothrombin activity >180 %, provided that 100 % corresponds to plasma 1 IU/ml prothrombin concentration, a risk of developing severe preeclampsia.
EFFECT: method enables providing more accurate prediction of developing severe preeclampsia.
1 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF THROMBOEMBOLIC COMPLICATIONS IN WOMEN ACCOMPANYING PROTROMBIN GENE MUTATIONS [F2(20210)GA] | 2019 |
|
RU2722280C1 |
| METHOD FOR PREECLAMPSIA PREDICTION IN PREGNANT WOMEN WITH MUTATION OF FACTOR V LEIDEN 1691 GENE OF G/A AND A/A GENOTYPE | 2016 |
|
RU2636228C1 |
| METHOD FOR PREVENTION OF PREECLAMPSIA IN CARRIERS OF F2G20210A MUTATION WITH SUPERTHRESHOLD INCREASE OF PROTHROMBIN ACTIVITY | 2019 |
|
RU2712444C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING PREECLAMPSIA IN WOMEN BASED ON GENETIC MARKERS | 2022 |
|
RU2795660C1 |
| METHOD OF PREDICTING RISK OF DEVELOPING PREECLAMPSIA IN PREGNANT WOMEN WITH FETAL GROWTH RESTRICTION | 2023 |
|
RU2808924C1 |
| METHOD OF PREECLAMPSIA PREVENTION IN PREGNANT WOMEN WITH MUTATION OF FACTOR V LEIDEN 1691 G/A | 2017 |
|
RU2666251C1 |
| METHOD FOR PREDICTION OF RISK OF MALIGNANT GROWTHS IN FEMALE GENITAL ORGANS AND MAMMARY GLANDS | 2014 |
|
RU2578459C1 |
| METHOD FOR PREDICTING EARLY PREECLAMPSIA ACCORDING TO THE LEVEL OF PROCOAGULANT ACTIVITY OF TISSUE FACTOR IN BLOOD PLASMA AT 19-21 WEEKS OF GESTATION IN PATIENTS OF THE LOW-RISK GROUP | 2022 |
|
RU2795083C1 |
| METHOD FOR PREDICTING THE RECURRENCE OF EARLY PREECLAMPSIA BY MARKERS OF ENDOTHELIAL DYSFUNCTION | 2022 |
|
RU2795090C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF PREECLAMPSIA IN PREGNANT WOMEN WITH FETAL GROWTH RESTRICTION SYNDROME | 2021 |
|
RU2754956C1 |
